title: Androgen receptor independent cardiovascular action of the antiandrogen flutamide.
abstract: We have previously shown that flutamide (specific antagonist of the androgen receptor) has antihypertensive effects. In the present study we examined the mechanisms of flutamide action in the vasculature. The vascular effects of flutamide were assayed in aortae isolated from male or female Sprague-Dawley rats and from rats or mice lacking a functional androgen receptor ( tfm, testicular feminization mutation). The effect of flutamide on coronary flow was tested in isolated hearts. In addition, male hypertensive rats with tfm mutation were treated with flutamide, and blood pressure was monitored. Flutamide induced a relaxation of rat aortae from all the strains used (maximum relaxation at 10 microM: 51.3+/-5.2% of phenylephrine contraction) and increased the coronary flow. The aortic relaxation to flutamide was abolished by endothelium removal, or by inhibition of nitric oxide synthase, guanylyl cyclase, and tyrosine kinase but not by calmodulin inhibition. Flutamide treatment attenuated the development of hypertension in mouse renin transgenic rats with the tfm mutation. Flutamide produces direct vasodilation by inducing release of NO from the endothelium and causes subsequent activation of soluble guanylyl cyclase in an active androgen receptor independent manner. This response may contribute to the observed antihypertensive actions of flutamide.
authors.affiliation: Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125 Berlin-Buch, Germany.
authors.forename: Radu
authors.initials: R
authors.lastname: Iliescu
authors.forename: Luciana A
authors.initials: LA
authors.lastname: Campos
authors.forename: Wolfgang-Peter
authors.initials: WP
authors.lastname: Schlegel
authors.forename: Ingo
authors.initials: I
authors.lastname: Morano
authors.forename: Ovidiu
authors.initials: O
authors.lastname: Baltatu
authors.forename: Michael
authors.initials: M
authors.lastname: Bader
mesh_terms: D000726:Androgen Antagonists / Q000494:pharmacology*; D000818:Animals; D030801:Animals, Genetically Modified; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001013:Aorta, Thoracic / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002320:Cardiovascular Physiological Phenomena / Q000187:drug effects*; D005260:Female; D005485:Flutamide / Q000494:pharmacology*; D006973:Hypertension / Q000235:genetics / Q000503:physiopathology*; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009154:Mutation; D051381:Rats; D020318:Rats, Long-Evans; D017207:Rats, Sprague-Dawley; D011944:Receptors, Androgen / Q000235:genetics / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000726:Androgen Antagonists; D000959:Antihypertensive Agents; D011944:Receptors, Androgen; D005485:Flutamide